: iStockAnalyst.com Symbols Feed

Dr. Reddy's Laboratories (RDY) Impressive On Both Fundamental And Technical Basis

Mon, 09 Nov 2009 17:00:18 GMT

While I've traded Dr. Reddy's Laboratories (RDY) in the past, I have not touched it in the past few years; however as we await for the new Market Vectors Indian Small Cap fund to launch I was poking my nose around Indian stocks this weekend since the Indian market has corrected quite a bit (and rebounded from oversold levels last week). So this name came back onto my radar in the limited universe of Indian ADRs. (full list of Indian stocks available at TickerSpy)[More...]

Pharma Majors To Gain From India

Wed, 19 Aug 2009 03:28:58 GMT

All major pharmaceutical companies that have operations in India are likely to benefit from the latest decision made by the Commerce Ministry in that country. The ministry accepted the Mashelkar committee’s report, according to which India will continue to allow patents on incremental innovations if the enhancements are beneficial to patients. The decision was taken amidst severe protests from generic players and health activists who fear this will not allow cheaper generic drugs to enter the market. On the basis of 2008 sales figures, the Indian pharmaceutical market ranks 13th in the world, with sales of $7.7bn last year (an increase of 4% over 2007). The rapidly growing middle income group with higher disposable income makes it an attractive place for major pharma companies. The pharmaceutical market is expected to grow at 12.3% through 2014 surpassing many other economies in the emerging markets. Many of these[More...]

Dr. Reddy's - Solid Q1 Growth - Analyst Blog

Tue, 21 Jul 2009 20:12:16 GMT

Dr. Reddy’s Posts Solid Growth in First Quarter of Fiscal 2010 Today morning, Dr. Reddy’s Laboratories (RDY) announced results for the first quarter ended June 30, 2009. The company posted impressive results with both revenue and earnings growing on a year-over-year basis. While total revenues came in at $381 million, up 21% y-o-y, the company reported earnings of $0.30 per diluted share, up 120% y-o-y. The company reports revenues from two segments: Global Generics and Pharmaceutical Services and Active Ingredients (PSAI). Revenues from the Global Generics business grew 27% to $273 million. Existing products and sumatriptan -- RDY’s generic version of GlaxoSmithKline’s ([More...]

Early Week Earnings Watch

Mon, 20 Jul 2009 14:10:12 GMT

2nd of the 3 big weeks for S&P 500 type companies arrives; last week was an unqualified success of setting expectations low, cutting expenses aggressively and beating very slow to adjust analysts expectations. Now with the bar raised higher as expectations ramped up, I expect the sledding to be a bit tougher. Here are names of interest in the early part of the week; with names the market will be watching and some additional ones that I like to look at. Tuesday will be the more interesting day. I forgot about earnings knee jerk reaction time, when I shorted American Express (AXP) and Capital One (COF) late Friday; both report Thursday so despite extreme overvaluations and gaps in each chart I'll be heading to the sidelines before then on the 2 positions.[More...]

Get Ready For Dr. Reddy's (NYSE: RDY)

Thu, 11 Jun 2009 17:21:47 GMT

India-based Dr. Reddy’s Laboratories (NYSE: RDY), a generic-drugs play with solid market positions in India, Russia, the US and Germany, says Asian stock expert Yiannis Mostrous.[More...]

With India, Long-Term Profit Potential Trumps Near-Term Concerns

Wed, 20 May 2009 11:51:05 GMT

By Martin Hutchinson Contributing Editor Money Morning India remains a great long-term profit play. But global investors should beware of the near-term exuberance that followed that... Money Morning is here to help investors profit handsomely on this seismic shift in the global economy. Money moves markets. But Money Morning lets you move first. [More...]

Healthcare Stock: Are They Truly Recession-Proof?

Thu, 22 Jan 2009 14:33:00 GMT

Healthcare Stocks…Are They Truly Recession-Proof? This past weekend, I was up at my hunting and fishing club in northeast Pennsylvania enjoying some ice fishing. At our club at least, it’s a pleasant social activity with great food, wine and stories shared among the members and spouses.This year, it happened to fall on the coldest day of the winter, with the temperature dipping to 18 below. As you might expect this close to the inauguration, many folks are wondering what effect President Obama’s policies will have on the markets and investing. One of our members who’s a doctor, said: “Invest in healthcare stocks. It doesn’t matter who’s in the Whitehouse, and they’re recession-proof.” Are they? The answer depends on what area of healthcare you’re talking about. According to [More...]

India’s Economy Standing Firm Amid the Growing Global Financial Crisis

Thu, 08 Jan 2009 16:13:00 GMT

(Editor's Note: This is the eleventh installment of our "Outlook 2009" series, which looks at the global investing outlook for the New Year.) By Mike Caggeso Associate Editor Money... Money Morning is here to help investors profit handsomely on this seismic shift in the global economy. Money moves markets. But Money Morning lets you move first. [More...]

Global Decline Spells Trouble For India’s Tech Sector

Tue, 09 Dec 2008 13:02:00 GMT

The deadly terrorist attacks in Mumbai, India dominated the global headlines last week. What didn't get a lot of attention, though, was the reason behind the attacks. The terrorists attacked the commercial heart of India — Mumbai's financial district. And I believe their purpose was to ...[More...]

Analysis Of Generic Drug Companies From India

Mon, 24 Nov 2008 16:14:00 GMT

The accompanying table includes the Top 25 rated companies with market caps over $50M U.S. Dollar which are included in the ETF Innovators (ETFI) Indian Generic Drug Index as a major component in the Global Generic Drug Index. The index also includes three companies based outside of India – Akorn (AKRX), Caraco Pharma (CPD), and Taro Pharma (TAROF). Akorn has a joint venture with Strides Arcolab (Akorn-Strides, LLC) which is focused on the hospital market for generic injectables, dominated by Hospira (HSP) and APP Pharma, which was acquired by Fresenius Medical (FMS).[More...]

U.S District Court Rules In Favor of Dr. Reddy's

Thu, 12 Mar 2009 15:49:23 GMT

India-based pharmaceutical company Dr. Reddy's Laboratories has said that the U.S. District Court for the Southern District of New York has ruled that the Omeprazole Mg OTC ANDA filed by Dr. Reddy's does not infringe the patents in suit related to Astra Zeneca's Prilosec OTC. .[More...]

AMRI Announces Third Quarter 2009 Results

Mon, 09 Nov 2009 11:47:00 GMT

Financial highlights for the quarter and other significant events include:
Total revenue for the third quarter of 2009 was $47.7 million, a decrease of 22% compared to total revenue of $61.4 million reported in the third quarter of 2008.
Total contract revenue encompasses revenue from AMRI's Discovery Services, Development and Small Scale Manufacturing, and Large Scale Manufacturing business components.

[More...]

Dr. Reddy's Q2 FY10 Results

Fri, 23 Oct 2009 09:48:00 GMT

Dr. Reddy's Laboratories Ltd. (NYSE:RDY) today announced its unaudited
(b) Includes forex gain of Rs. 244 million in Q2 FY10.
(c) Includes forex loss of Rs. 296 million in Q2 FY09.

[More...]

Ceragenix and MEGAPHARM Enter Into Distribution and Supply Agreement for EpiCeram®

Mon, 27 Jul 2009 11:47:00 GMT

Ceragenix Pharmaceuticals, Inc.("Ceragenix") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the "Agreement") with Megapharm Ltd., an Israeli company, ("Megapharm"), to commercialize EpiCeram®, a topical cream for treating atopic dermatitis and other dry skin conditions in Israel and the Palestinian territories (the "Territory").
Megapharm is also responsible for obtaining regulatory clearance to market EpiCeram® in the Territory.
These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, the following: the ability of Megapharm to successfully obtain marketing clearance for EpiCeram® in the Territory, the ability of the Company to raise sufficient capital to finance its operations and planned activities including completing development of its Ceragenin technology; the ability of the Company to meet its obligations under the supply and distribution agreement with Dr.Reddy's Laboratories including having sufficient working capital to fulfill purchase orders within the timeframes required by the agreement; the ability of the Company to service its outstanding convertible debt obligations; receiving the necessary marketing clearance approvals from the United States Food and Drug Administration (the "FDA"); successful clinical trials of the Company's planned products including the ability to enroll the studies in a timely manner, patient compliance with the study protocol, and a sufficient number of patients completing the studies; the ability of the Company to commercialize its planned products; the ability of the Company to successfully manufacture its products in commercial quantities (through contract manufacturers); market acceptance of the Company's planned products, the Company's ability to successfully develop its licensed compounds, alone or in cooperation with others, into commercial products, the ability of the Company to successfully prosecute and protect its intellectual property, general economic conditions in the United States and elsewhere, and the Company's ability to hire, manage and retain qualified personnel.

[More...]

Dr. Reddy’s Q1 FY10 Results

Tue, 21 Jul 2009 11:39:00 GMT

Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) today announced its unaudited financial results for the first quarter ended June 30, 2009 under International Financial Reporting Standards (IFRS).[More...]

Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F

Wed, 08 Jul 2009 08:08:00 GMT

Dr. Reddy's Laboratories Limited (NYSE:RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2009 was filed with the United States Securities and Exchange Commission on 6th July 2009.
The Annual Report on Form 20-F is also available on Dr. Reddy's corporate website, www.drreddys.com and can be accessed by selecting ˜SEC filings' under the ˜Investors' Section.
ADS holders may also obtain a hard copy of the Annual Report on Form 20-F or Indian Annual Report, free of charge, by sending a written request to the Company's registered office or by sending an e-mail to shares@drreddys.com.

[More...]

Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F

Wed, 08 Jul 2009 07:12:00 GMT

Dr. Reddy’s Laboratories Limited (NYSE:RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2009 was filed with the United States Securities and Exchange Commission on 6th July 2009.[More...]

Dr. Reddy’s Announces Strategic Alliance with GSK for Emerging Markets

Mon, 15 Jun 2009 13:23:00 GMT

Dr. Reddy’s Laboratories (NYSE: RDY) today announced a partnership with GlaxoSmithKline plc (GSK) to develop and market select products across emerging markets outside India.[More...]

Dr. Reddy’s Announces ANDA Approval of Omeprazole Mg OTC

Tue, 09 Jun 2009 13:46:00 GMT

Dr. Reddy’s Laboratories (NYSE:RDY) today announced that the U.S. Food and Drug Administration has granted approval of the Company’s Abbreviated New Drug Application (ANDA) for Omeprazole Mg OTC. Shipment of the product will be phased over the remainder of the fiscal year 2010 with the first shipment likely to commence in early Q2 of fiscal year 2010.[More...]

Dr. Reddy’s Receives Approval for Three INDs and Announces Reorganization of Its Drug Discovery Operations

Fri, 22 May 2009 07:05:00 GMT

Dr. Reddy’s announced that the first human subjects were successfully dosed in a phase I study with DRL 17822, a selective inhibitor of CETP, for the treatment of dyslipidemia, atherosclerosis and associated cardiovascular diseases. The compound shows potent elevation in HDL-C and reduction of atherosclerotic plaques in animals, and has a clean safety profile in preclinical studies. The two other IND’s are for the treatment of COPD and dyslipidemia.[More...]

Ceragenix Enters into Second Exclusive Option to License Agreement for Antimicrobial Medical Device

Mon, 11 May 2009 11:53:00 GMT

Ceragenix Pharmaceuticals, Inc.("Ceragenix") (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that it has entered into an exclusive evaluation and option to license agreement (the "Agreement") with a global, multi-billion dollar healthcare company covering the use of the Company's Cerashield antimicrobial technology for a specific medical device associated with a high incidence of hospital acquired infections.
This is the second such agreement entered into by Ceragenix for a medical device application of its CeraShield antimicrobialtechnology.
Mr. Steven Porter, Chairman and CEO of Ceragenix said: "We're very pleased to announce our second development agreement involving our CeraShield antimicrobial coating technology.

[More...]